The Cannabis Act going into effect brought drastic changes to both the recreational and medical marijuana industries in Canada last week, with news arriving daily of new ventures and new products since legalization arrived.

Some of those changes have managed to reach across the border as Canadian companies look south, especially with legalization expected to arrive in several additional US states with the coming November elections.

British Colombia-based medical cannabis producer Emerald Health Therapeutics Inc. (TSXV:EMH) just announced the filing of 17 provisional US patent applications covering Defined Dose cannabis dosage  formulations. The company issued this statement regarding the patents:

“Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.  The products provide more precise and consistent delivery, dosage, and formulations.”

The seventeen Defined Dose cannabis patent applications relate to:

  • Inhaled dosage forms for smoking
  • Inhaled dosage forms for vaping
  • Capsule and edible formulations based on cannabinoid molecular pathways and how they influence disease mechanisms

While some of the Defined Dose cannabis products are eligible for launch in Canada under existing Canadian regulations, others are expected to become eligible under anticipated regulatory changes in 2019.

Emerald CEO Chris Wagner commented:

“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science.”

Wagner went on to add, “Emerald’s filing of these patent applications is an important step. Our expanding research and development effort is focused on internal facilities and staff as well as forming key relationships with other cannabis research experts, such as our recently announced agreement with VivaCell Biotechnologies Espana.”

Although cannabis is not federally legal in the United States for commercial purposes, that hasn’t stopped Canadian companies from getting involved in the American market.

Aurora Cannabis applied to trade on the New York Stock Exchange last week for instance, with Aphria following suit and also filing to list on the NYSE. Chicago-based Cresco Labs meanwhile is moving in the opposite direction, going public in Canada via a reverse takeover of Randsburg International.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.